The therapeutic potential of simultaneously blocking BCL-xL and MCL-1 has been reported in many cancers [39, 68, 69], and we recently demonstrated this strategy in ER + breast cancer using a sequential regime [51], although BCL-xL induced thrombocytopenia may challenge its clinical implementation. The gene discussed is MCL1; the disease is Thrombocytopenia.